Live Chat

Trade Gilead GILD

Gilead live chart

Instrument Fundamentals

Weekly Search
Weekly
Daily
date Close change Change (%) Open High Low

Latest news

Frances Wang 2024 Dec 02, 16:00

Gold Price Dropped Below $2,650 as US Dollar Rises on Trump Tariff Threat

Commodities
Frances Wang 2024 Dec 02, 16:00

GBP to USD forecast: GBP/USD Records Its Best Week Since September

Forex
Frances Wang 2024 Dec 02, 16:00

Supermicro stock surged almost 30%: Why SMCI Stock Is Surging Again?

Stocks
Frances Wang 2024 Dec 02, 16:00

BTC Price Forecast and Bitcoin Technical Analysis: Will Bitcoin Reach $100K?

Cryptocurrencies
Neil Wilson 2024 Dec 02, 16:00

Week Ahead: Markets on the Move: Stocks Rally Amid Economic Uncertainty

Stocks Morning Note
Frances Wang 2024 Dec 01, 16:00

Forex market news: Japanese Yen Sharply Declines Against USD

Forex
Frances Wang 2024 Dec 01, 16:00

Solana Price Prediction: Will SOL Hit $1,000 after its impressive rebound

Cryptocurrencies
Frances Wang 2024 Dec 01, 16:00

FTSE 100 Index Today: FTSE 100 companies recognize supply chain as key risk

Indices

Info

Spread

0.60

Spread (%)

0.6380 %

Leverage

1:5

Overnight Interest Buy

-0.0597 %

Overnight Interest Sell

-0.0292 %

Currency

USD

Trading Hours

Market open

Tuesday

14:31 - 20:59

Monday

14:31-20:59

Wednesday

14:31-20:59

Thursday

14:31-20:59

Friday

14:31-20:59

Analysis and statistics

Open

---

Previous Close

---

52 Week High/Low

--- – ---

Market cap

117174296576

Shares Outstanding

1246269952

Earnings Date (Next)

2013-01-28

instr__dividend_date

2024-12-30

instr__ex_dividend_date

2024-12-13

instr__forward_annual_dividend_rate

3.08

instr__forward_annual_dividend_yield

0.0328

EPS

0.09

Learn more about this instrument

Gilead Gilead Sciences Inc
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Related Instruments

Asset
Sell
Buy
Change (%)
View all instruments
Trustpilot
Live Chat